Global Peripheral Neuropathy Treatment Market 2024-2028

Global Peripheral Neuropathy Treatment Market 2024-2028

The peripheral neuropathy treatment market is forecasted to grow by USD 447.3 mn during 2023-2028, accelerating at a CAGR of 4.36% during the forecast period. The report on the peripheral neuropathy treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of peripheral neuropathy, recent drug approvals for peripheral neuropathy, and rising awareness of peripheral neuropathy.

Technavio's peripheral neuropathy treatment market is segmented as below:

By Type

• Diabetic peripheral neuropathy
• Chemotherapy induced peripheral neuropathy
• Others

By Therapy

• Pharmacological therapies
• Non pharmacological therapies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the strong drug pipeline as one of the prime reasons driving the peripheral neuropathy treatment market growth during the next few years. Also, technological advances with new formulations of drugs and rising penetration of generic drugs will lead to sizable demand in the market.

The report on the peripheral neuropathy treatment market covers the following areas:

• Peripheral neuropathy treatment market sizing
• Peripheral neuropathy treatment market forecast
• Peripheral neuropathy treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading peripheral neuropathy treatment market vendors that include Apotex Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Cadila Pharmaceuticals Ltd., Cipla Inc., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Grunenthal GmbH, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc.. Also, the peripheral neuropathy treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.